Strategy for randomised clinical trials in rare cancers.
about
Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design.Rare cancers: Challenges & issues.Bridging the gap: a review of dose investigations in paediatric investigation plansRare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper.On the evolution of statistical methods as applied to clinical trials.Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers InitiativeDiagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.The End-of-Life Experience of Patients With Rare Cancers and Their Caregivers.Looking ahead: clinical trial design in adult congenital heart disease.Innovative research methods for studying treatments for rare diseases: methodological review.Good-quality research in rare diseases: trials and tribulations.Drug development challenges and strategies to address emerging and resistant fungal pathogens.New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study.Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma.Bayesian survival analysis in clinical trials: What methods are used in practice?Alternative designs for clinical trials in rare diseases.Bayesian methods for the design and interpretation of clinical trials in very rare diseases.Trials in rare diseases: the need to think differently.Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.Emerging Opportunities for Target Discovery in Rare Cancers.Evidence-Based Medicine and Rare Diseases.Prior distributions for the intracluster correlation coefficient, based on multiple previous estimates, and their application in cluster randomized trials.A survey of physician's attitudes regarding management of severe group A streptococcal infections.
P2860
Q27853146-78AF360F-F1F5-44F3-9E2B-1AAB0311CFFEQ31106969-FD6795B3-A416-497C-87EB-9CD71D568680Q33768543-B4F01F0A-4013-4625-A7FE-B43DEA4E86AEQ34554486-5E163FFC-6642-4071-87F0-2CFC8869CFAFQ35005736-5A3586A1-3E10-4A25-AA07-F02CB930A1F9Q35743841-9B9E4066-E5F5-4948-9922-CC3160074BFFQ36265620-4C5BADDF-6929-40C7-B64F-46CC61B601C9Q37263146-0C588D66-2A21-4534-8BF2-E116C203F2FCQ37671153-F7320513-861B-480D-AE44-AA69DACC9F4BQ37687391-488A2ECB-2DD4-426E-9122-BA56BBD936B4Q37993151-7AAB67F0-FE2F-4351-943A-1E175F7CE26AQ38271185-5B710DB5-9134-49EC-A8C3-28D19F3E7780Q38713946-67E72A01-DDE3-40C0-8845-EF088C9677E6Q38798805-37E8D58A-B3B3-4F6E-9409-07BF932C548FQ38888445-E5D07BF0-BB09-415F-A1C8-36CF680D3EF3Q38944582-F15AE22C-C07A-46A1-BCEF-D3049F6B0CD2Q38978314-431C70F1-34AB-409A-8520-BF53FF7D6617Q39013156-1C84201C-B255-405F-A2F0-9D235F5A9B59Q41908823-C238DAC8-07A0-4F18-AE61-92E008ABFC89Q46003924-B3455DB0-850E-4CC6-AC2A-45416F1599F5Q47254055-CE218911-7C0B-4B9E-ADD6-F3A36EF49C1AQ47941750-2977ECF3-CF1E-457E-BE7A-4F78FD6995D7Q50041285-EAC19083-00CB-407E-B181-C7D0EF6F55DDQ51960436-C728FB67-ACCE-47C2-8609-89832E4DA9FCQ53214806-2E2CA378-00CB-4247-A763-227E22413CF9
P2860
Strategy for randomised clinical trials in rare cancers.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Strategy for randomised clinical trials in rare cancers.
@ast
Strategy for randomised clinical trials in rare cancers.
@en
type
label
Strategy for randomised clinical trials in rare cancers.
@ast
Strategy for randomised clinical trials in rare cancers.
@en
prefLabel
Strategy for randomised clinical trials in rare cancers.
@ast
Strategy for randomised clinical trials in rare cancers.
@en
P2093
P2860
P356
P1433
P1476
Strategy for randomised clinical trials in rare cancers.
@en
P2093
David Machin
Keith B G Dear
Paolo Bruzzi
Say-Beng Tan
P2860
P356
10.1136/BMJ.327.7405.47
P407
P577
2003-07-01T00:00:00Z